Revenue rise for pharma firm as take-up increases

PHARMACEUTICAL firm Shield Therapeutics has seen revenues rise as more markets adopt its leading iron deficiency product.

- COREENA FORD Business writer [e-mail]

The maker of iron deficiency-fighting tablets, which has operations in the North East and the US, has been involved in a significant push of its iron deficiency-fighting tablets, sold in Europe as Ferracru and all other territories as Accrufer, with a prime focus on the US.

In its latest note to investors, covering results for the six months to June 30, the Gateshead-based pharma firm reported a substantial increase in group revenues, prescription sales and its average net selling price.

Group revenues rose from $12.1m to $21.4m, and Accrufer revenue increased from $1lm to $19.2m. It said revenues were generated through around 84,000 prescriptions predominantly in the six large states of Texas, New York, Florida, Georgia, California, and North Carolina.